Global Human Vaccines Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

The global human vaccines market exhibits segmentation across multiple dimensions, including vaccine type, age group, and geography, reflecting the diverse needs and preferences of consumers and healthcare systems worldwide. One significant segmentation criterion is based on vaccine type, distinguishing between prophylactic vaccines and therapeutic vaccines. Prophylactic vaccines aim to prevent infectious diseases by stimulating the immune system to recognize and defend against specific pathogens, offering protection against diseases such as measles, influenza, hepatitis, and human papillomavirus (HPV). These vaccines target populations of all ages, from infants receiving childhood immunizations to adults receiving booster doses and travel vaccines. Therapeutic vaccines, on the other hand, are designed to treat existing diseases or conditions by stimulating the immune system to target and eliminate cancer cells, infectious agents, or autoimmune disorders. These vaccines represent a promising frontier in personalized medicine, offering potential treatments for conditions such as cancer, HIV/AIDS, and Alzheimer's disease.

Human vaccines market pertains to age-based segmentation, distinguishing between pediatric vaccines, adult vaccines, and geriatric vaccines. Pediatric vaccines target infants, children, and adolescents, offering protection against common childhood diseases such as measles, mumps, rubella, pertussis, and varicella. These vaccines are administered according to recommended immunization schedules, ensuring timely protection against vaccine-preventable diseases during critical stages of development. Adult vaccines cater to individuals aged 18 and older, addressing specific health needs and risk factors associated with adulthood, such as influenza, pneumococcal disease, shingles, and human papillomavirus (HPV). Geriatric vaccines target older adults aged 65 and older, addressing age-related declines in immune function and susceptibility to vaccine-preventable diseases such as influenza, pneumococcal disease, and herpes zoster. Age-based segmentation enables healthcare providers to tailor vaccination strategies and recommendations to meet the unique needs and vulnerabilities of different age groups, optimizing vaccine coverage and disease prevention efforts.

Global Human Vaccines Segment Analysis

In this report, the Global Human Vaccines Market has been segmented by Vaccine Type, Product, Distribution Channel, Age Group, and Geography.

Global Human Vaccines Market , Segmentation by Vaccine Type

The Global Human Vaccines Market has been segmented by Vaccine Type into Conjugate, Recombinant, Conjugate Vaccines, Inactivated, Combination, Attenuated, and Others.

Conjugate vaccines represent a significant portion of the market share, characterized by their ability to enhance immune responses and provide long-lasting protection against bacterial infections. Conjugate vaccines consist of antigens linked to carrier proteins, enabling the immune system to recognize and respond to specific pathogens more effectively. These vaccines are widely used to prevent diseases such as pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) infection. Companies specializing in conjugate vaccine technology have developed innovative formulations and delivery systems to improve vaccine efficacy, safety, and accessibility.

Recombinant vaccines have gained prominence in the vaccine market due to their precise antigen design and manufacturing processes. Recombinant vaccines are produced by genetic engineering techniques, where specific genes encoding antigenic proteins are inserted into host cells to produce vaccine antigens. These vaccines offer advantages such as improved safety profiles, reduced risk of contamination, and rapid scalability. Recombinant vaccines are used to prevent diseases such as hepatitis B, human papillomavirus (HPV), and shingles (herpes zoster). Companies focusing on recombinant vaccine development have contributed to advancements in vaccine technology, antigen design, and production methods.

Inactivated vaccines, also known as killed vaccines, consist of pathogens that have been rendered non-infectious through physical or chemical methods. These vaccines stimulate an immune response without causing disease, providing protection against viral and bacterial infections. Inactivated vaccines are widely used in routine immunization programs and outbreak control efforts, offering safe and effective protection against diseases such as influenza, polio, and rabies. Companies specializing in inactivated vaccine manufacturing adhere to stringent quality control standards to ensure vaccine safety, potency, and efficacy.

Combination vaccines combine multiple antigens from different pathogens into a single vaccine formulation, providing protection against several diseases with a single injection. Combination vaccines offer advantages such as simplified immunization schedules, reduced healthcare costs, and improved vaccine coverage rates. These vaccines are commonly used in pediatric immunization schedules to prevent diseases such as diphtheria, tetanus, pertussis, measles, mumps, rubella, and hepatitis B. Companies developing combination vaccines focus on optimizing antigen combinations, adjuvant formulations, and vaccine delivery technologies to maximize immunogenicity and safety.

Attenuated vaccines, also known as live vaccines, contain weakened forms of pathogens that stimulate immune responses without causing severe disease. These vaccines closely mimic natural infection, providing robust and long-lasting immunity against viral diseases. Attenuated vaccines are used to prevent diseases such as measles, mumps, rubella, varicella (chickenpox), and yellow fever. Companies specializing in attenuated vaccine development employ sophisticated attenuation techniques to balance vaccine safety with immunogenicity, ensuring optimal vaccine performance and protection.

Global Human Vaccines Market , Segmentation by Product

The Global Human Vaccines Market has been segmented by Product into Pneumococcal, Influenza, Hepatitis, HPV, Meningococcal, Rotavirus, Measles & Rubella, Typhoid, Combination, and Others.

Pneumococcal conjugate vaccines has significantly contributed to the decline in pneumococcal disease incidence and associated complications worldwide, making them indispensable components of routine immunization programs and public health strategies.

Pneumococcal vaccines, the global human vaccines market includes influenza vaccines, which target influenza viruses responsible for seasonal flu outbreaks and pandemics. Influenza vaccines undergo annual updates to match circulating virus strains and provide optimal protection against influenza-related illness, hospitalization, and mortality. These vaccines are recommended for individuals of all ages, particularly those at high risk of severe complications from influenza, such as young children, older adults, pregnant women, and individuals with underlying health conditions. The widespread adoption of influenza vaccination plays a critical role in reducing the spread of influenza viruses, minimizing healthcare burdens, and safeguarding public health during flu seasons.

Global human vaccines market encompasses a diverse array of vaccines targeting hepatitis, human papillomavirus (HPV), meningococcal disease, rotavirus infection, measles and rubella, typhoid fever, and other infectious diseases. Hepatitis vaccines protect against viral hepatitis caused by hepatitis A virus (HAV) and hepatitis B virus (HBV), reducing the risk of liver inflammation, cirrhosis, and liver cancer. HPV vaccines prevent HPV infection and related cancers, including cervical, anal, and oropharyngeal cancers, through targeted immunization of adolescents and young adults. Meningococcal vaccines offer protection against Neisseria meningitidis bacteria, which can cause meningitis and bloodstream infections, particularly among adolescents, college students, and travelers to meningitis-endemic regions.

Rotavirus vaccines prevent severe diarrhea and dehydration caused by rotavirus infection, reducing childhood morbidity and mortality rates worldwide. Measles and rubella vaccines contribute to the elimination of measles and rubella transmission, preventing outbreaks and associated complications such as encephalitis, pneumonia, and congenital rubella syndrome. Typhoid vaccines offer protection against typhoid fever, a bacterial infection transmitted through contaminated food and water, prevalent in regions with inadequate sanitation and hygiene practices. Combination vaccines integrate multiple antigens into a single formulation, simplifying vaccination schedules and enhancing vaccine coverage rates, particularly in pediatric immunization programs.

Global Human Vaccines Market , Segmentation by Distribution Channel

The Global Human Vaccines Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Hospital pharmacies represent a significant portion of the market share, serving as primary distribution points for vaccines in healthcare settings. Hospitals and healthcare facilities procure vaccines directly from manufacturers or wholesalers and distribute them to patients through on-site pharmacies. Hospital pharmacies play a critical role in immunization programs, providing vaccines to patients during routine healthcare visits, emergency situations, and public health campaigns. They offer convenience, accessibility, and expertise in vaccine administration, ensuring timely and appropriate vaccination for patients of all ages.

Retail pharmacies also hold a considerable market share, providing vaccines to consumers through community-based pharmacy outlets. Retail pharmacies, including chain pharmacies, independent pharmacies, and drugstore retailers, offer a convenient and accessible option for individuals to receive vaccines outside of traditional healthcare settings. Pharmacists and pharmacy staff administer vaccines, educate patients about vaccine benefits and risks, and maintain vaccine storage and handling protocols to ensure vaccine efficacy and safety. Retail pharmacies play a vital role in expanding vaccine access, particularly for routine vaccinations, travel immunizations, and seasonal flu shots.

Online pharmacies represent an emerging distribution channel in the vaccine market, offering vaccines for purchase and delivery through e-commerce platforms and online ordering systems. Online pharmacies provide consumers with the convenience of ordering vaccines from the comfort of their homes and receiving them via mail or delivery services. While online pharmacies may not offer vaccine administration services directly, they facilitate access to vaccines by providing information, product selection, and convenient ordering options. Online pharmacies adhere to regulatory requirements and quality standards to ensure the safety and authenticity of vaccines sold through their platforms.

Global Human Vaccines Market , Segmentation by Age Group

The Global Human Vaccines Market has been segmented by Age Group into Pediatrics, Adolescents, Adults, and Geriatric.

Pediatric vaccines, the global human vaccines market addresses the vaccination needs of adolescents, offering vaccines specifically designed for this age group. Adolescent vaccines target adolescents aged 11 to 18 years, providing protection against diseases such as human papillomavirus (HPV), meningococcal disease, influenza, tetanus, diphtheria, pertussis, and hepatitis B. Vaccination during adolescence helps protect individuals during a period of increased social interaction, lifestyle changes, and risk-taking behaviors, reducing the risk of vaccine-preventable infections and their associated complications. Adolescent vaccination programs aim to promote health equity, prevent disease transmission, and establish a foundation for lifelong health and well-being among young people.

Adult vaccines target individuals aged 18 years and older, providing protection against diseases such as influenza, pneumococcal disease, shingles, hepatitis B, human papillomavirus (HPV), tetanus, diphtheria, pertussis, and meningococcal disease. Vaccination during adulthood helps maintain immunity against vaccine-preventable diseases, reduce disease transmission in communities, and protect individuals with chronic health conditions or weakened immune systems. Adult vaccination programs aim to promote healthy aging, prevent vaccine-preventable morbidity and mortality, and enhance quality of life among adults of all ages.

Geriatric vaccines target age-related declines in immune function, increased susceptibility to infections, and higher risk of complications from vaccine-preventable diseases. Vaccines recommended for older adults include influenza, pneumococcal disease, herpes zoster, and tetanus, diphtheria, pertussis (Tdap) vaccines. Vaccination during later life stages helps protect older adults from serious illnesses, reduce healthcare costs, and promote healthy aging and independent living. Geriatric vaccination programs aim to improve vaccination coverage rates, reduce the burden of vaccine-preventable diseases, and enhance the health and well-being of older populations worldwide.

Global Human Vaccines Market, Segmentation by Geography

In this report, the Global Human Vaccines Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Human Vaccines Market Share (%), by Geographical Region, 2023

North America retained a significant portion of the market share, capturing approximately 30% of the total. This dominance can be attributed to factors such as robust immunization programs, high healthcare spending, and strong demand for vaccines across diverse age groups. Countries like the United States and Canada have well-established vaccination systems, with comprehensive vaccine coverage for diseases such as influenza, measles, and HPV. Additionally, ongoing efforts to address emerging infectious diseases and public health threats contribute to sustained market growth in the region.

Europe followed closely behind, holding around 25% of the market share. The European market for human vaccines continued to expand due to government-funded immunization programs, increasing awareness of vaccine-preventable diseases, and advancements in vaccine technology. Countries within the European Union, such as Germany, France, and the United Kingdom, have made significant investments in vaccine research, development, and distribution, resulting in high vaccination coverage rates and improved public health outcomes.

Asia Pacific emerged as a key player in the global human vaccines market, accounting for approximately 35% of the total market share. Rapid population growth, urbanization, and rising healthcare expenditure in countries like China, India, and Japan have contributed to significant market growth in the region. Governments in Asia Pacific have prioritized vaccination as a cornerstone of public health policy, leading to expanded vaccine coverage and increased demand for new and existing vaccines. Moreover, the emergence of infectious disease outbreaks such as COVID-19 has underscored the importance of vaccination in controlling pandemics and driving market growth in the region.

The remaining market share was distributed among other regions, including Latin America, the Middle East, and Africa, each contributing to the global market to varying degrees. These regions face unique challenges related to vaccine access, affordability, and infrastructure but offer significant growth opportunities for vaccine manufacturers and distributors. Efforts to strengthen healthcare systems, improve vaccine distribution networks, and address vaccine hesitancy are essential for expanding vaccine coverage and reducing the burden of vaccine-preventable diseases in these regions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Human Vaccines Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Increasing Disease Burden
• Rising Global Population
• Government Immunization Programs

• Technological Advancements in Vaccine Development - Technological advancements in vaccine development are revolutionizing the field of immunization, enabling the creation of safer, more effective, and innovative vaccines to combat a wide range of infectious diseases. These advancements encompass various aspects of vaccine development, from antigen identification and formulation to delivery mechanisms and manufacturing processes.

  Advancements in vaccine adjuvants and formulation technologies have enabled the development of vaccines with improved efficacy, safety, and stability. Adjuvants enhance the immune response to vaccines by stimulating innate immune pathways and promoting antigen presentation, allowing for lower antigen doses and fewer vaccine doses to achieve protective immunity. Additionally, novel formulation approaches, such as lipid nanoparticles and virus-like particles, enable the delivery of vaccines with enhanced stability and immunogenicity, expanding the range of vaccine targets and improving vaccine storage and distribution.

  Technological innovations in vaccine delivery systems are transforming the way vaccines are administered, improving vaccine coverage and accessibility. Novel delivery platforms, such as microneedle patches, oral vaccines, and needle-free injection devices, offer alternative routes of administration that are more convenient, painless, and cost-effective than traditional needle-based injections. These technologies enable self-administration, reduce the need for trained healthcare personnel, and facilitate mass vaccination campaigns, particularly in resource-limited settings or during public health emergencies.

Restraints

• Vaccine Hesitancy and Misinformation
• High Development Costs
• Stringent Regulatory Requirements

• Supply Chain Challenges - Supply chain challenges pose significant obstacles to the efficient distribution and delivery of vaccines, impacting their availability, accessibility, and affordability, particularly in resource-constrained settings. These challenges encompass various aspects of the vaccine supply chain, from manufacturing and distribution to storage and administration, and can have far-reaching implications for public health efforts, immunization coverage, and disease control strategies.

  Supply chain challenges are exacerbated by the stringent storage and handling requirements of many vaccines, particularly those that require cold chain storage. Vaccines are highly sensitive biological products that can lose potency if exposed to improper temperatures, light, or handling conditions during transportation and storage. Maintaining the integrity of the cold chain, especially in remote or underserved areas with limited infrastructure and resources, presents significant logistical challenges and requires robust monitoring, refrigeration, and quality assurance measures to ensure vaccine efficacy and safety.

  Supply chain disruptions, such as natural disasters, geopolitical conflicts, and global health emergencies, can disrupt vaccine production, distribution, and delivery, leading to shortages and stockouts. These disruptions can have devastating consequences for immunization programs, jeopardizing public health efforts to control vaccine-preventable diseases and leaving vulnerable populations at risk of infection. Additionally, the COVID-19 pandemic has highlighted the vulnerabilities of the vaccine supply chain, exposing weaknesses in global coordination, resilience, and preparedness, and underscoring the need for greater investment in supply chain infrastructure and resilience.

Opportunities

• Expansion of Immunization Programs
• Development of Novel Vaccines
• Increasing Investments in Preventive Healthcare

• Emerging Markets Expansion - The expansion of vaccine markets into emerging economies presents significant opportunities for vaccine manufacturers and public health organizations to address unmet medical needs, improve healthcare access, and drive economic development. Emerging markets, characterized by rapidly growing populations, rising incomes, and increasing urbanization, represent a growing demand for vaccines to prevent infectious diseases and protect public health.

  Growing awareness of the importance of vaccination in preventing and controlling infectious diseases. As healthcare infrastructure improves and public health education efforts increase, demand for vaccines among healthcare providers, policymakers, and the general population in emerging markets is rising. Governments and international organizations are prioritizing immunization programs as part of broader public health initiatives to reduce disease burden, improve child health outcomes, and achieve universal health coverage goals.

  Expansion of vaccine markets into emerging economies is driven by advancements in vaccine manufacturing and distribution technologies, as well as strategic partnerships between vaccine manufacturers, governments, and international organizations. Vaccine manufacturers are investing in expanding their production capacities, developing new vaccine formulations, and optimizing supply chain logistics to meet the growing demand for vaccines in emerging markets. Additionally, collaborations between public and private sector stakeholders are facilitating technology transfer, capacity-building initiatives, and knowledge exchange to strengthen local vaccine production capabilities and improve access to affordable vaccines.

Key players in Global Human Vaccines Market include :

• AstraZeneca
• Bavarian Nordic
• Bharat Biotech
• CSL Limited
• Emergent BioSolutions
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis